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ABSTRACT 
α-GalCer analogues featuring a phytoceramide 3- and 4-amino group have been synthesized. A Mitsunobu reaction 
involving phthalimide was employed for the introduction of the amino groups at the 3- and 4-positions of suitable 
phytosphingosine-derived precursors. The influence of these modifications on the interaction with the T-cell 
receptor of NKT cells was investigated, as well as the capacity of the amino-modified analogues to induce a cytokine 
response after in vivo administration.  
In the past decade, glycolipids have gained increasing 
interest as immune modulatory agents due to their role in 
the defence against microbial infections, tumor immuno-
surveillance and the maintenance of immune tolerance.1 
In that context, the most extensively studied glycolipid is 
α-GalCer (1, aka KRN7000),2
                                                     
† Laboratory for Medicinal Chemistry, Ghent University. 
 of which high specificity 
‡ Department of Rheumatology, Ghent University. 
║ Division of Cell Biology, La Jolla Institute for Allergy and 
Immunology. 
¶ School of Chemistry, University of Southampton. 
1 Reviews: (a) Wu, D.; Fujio, M.; Wong, C.H. Bioorg. Med. Chem. 
2008, 16, 1073. (b) Savage, P.B.; Teyton, L.; Bendelac, A. Chem. Soc. 
Rev. 2006, 35, 771.  
2 (a) Morita, M. ; Motoki, K.; Akimoto, K.; Natori, T.; Sakai, T.; 
Sawa, E.; Yamaji, K.; Koezuka, Y.; Kobayashi, E.; Fukushima, H. J. 
Med. Chem. 1995, 38, 2176. (b) Natori, T.; Koezuka, Y.; Higa, T. 
for CD1d, a cell surface glycoprotein constitutively 
expressed by antigen presenting cells, is well-established. 
Upon recognition of the α-GalCer-CD1d complex by their 
semi-invariant T-cell receptor (TCR), Natural Killer T 
(NKT) cells are activated, resulting in the rapid release of 
T helper 1 (Th1) and T helper 2 (Th2) cytokines. The 
concomitant release of Th1 and Th2 cytokines, which 
antagonize each other’s effects, is believed to limit α-
GalCer’s therapeutic outcome. Hence, the development of 
analogues capable of inducing a biased Th1 or Th2 
response is highly promising.3
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Crystal structures of human4 and mouse5 CD1d 
complexed with α-GalCer or the ternary structures also 
comprising the human6 and mouse7 NKT TCR reveal that 
the galactose ring is well ordered and extends above the 
surface of a lipid-binding groove. Several hydrogen bonds 
between 1 and CD1d are assumed to anchor α-GalCer in a 
proper orientation for recognition by the TCR.8
The hypothesis stating that the Th1-Th2 balance is 
determined by the overall stability of the CD1d-
glycolipid-TCR complex
 Asp-80 
was found to interact with both secondary hydroxy groups 
(i.e., 3-OH and 4-OH) of the phytosphingosine backbone. 
A key interaction of the subsequent NKT TCR binding 
involves a hydrogen bond between the TCR Arg-95 
residue and the same 3-OH group.  
 is a matter of debate. Many 
analogues, typically obtained by modifying the apolar 
regions of 1, have been synthesised in order to investigate 
this relationship,9,10,11 but recent studies also point toward 
the importance of the mode of glycolipid loading into 
CD1d and the rate of glycolipid dissociation from CD1d 
in the lysosomes.12
From the X-ray data, it can be concluded that α-
GalCer’s 3-OH is a crucial group as it interacts both with 
CD1d and the TCR. Hence we proposed to investigate the 
3- and 4-amino-3-(4-)deoxy analogues 2–5, as it was 
anticipated that ionic interactions would be established 
with the CD1d Asp-80, leading to increased complex 
stability. On the other hand, the interaction with the TCR 
would also be affected by such modifications since a 3-
ammonium group can no longer act as hydrogen bond 
acceptor and the inductive effect of the 4-ammonium 
group was expected to severely weaken the hydrogen 
bond acceptor capacity of the 3-OH. 
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Synthetic procedures towards the desired 2,3-diamino-
1,4-butanediol or 2,4-diamino-1,3-butanediol aglycon 
scaffolds are scarce. Noteworthy is the recently reported 
enantioselective synthesis of a O-1-protected 4-deoxy-4-
azido-2-phthalimido-D-ribo-phytosphingosine, involving a 
regioselective opening of a cyclic sulfate.13 The structure 
of prumycin, an antibiotic isolated in 1971 that is 
synthetically accessible,14
 
 contains a 2,4-diamino-1,3-
butanediol moiety with a configuration matching that of 
the desired L-lyxo analogue 5.  
Figure 1. Structures of KRN7000 (1) and amino-modified 
analogues (2-5). 
  
However, for the synthesis of the four desired glycosyl 
acceptors, it was decided to use a common strategy 
starting from D-ribo-phytosphingosine, which is now 
readily available from a yeast fermentation process.  
The synthesis of the 3-amino-3-deoxy-α-GalCer 
epimers is shown in Scheme 1. D-ribo-phytosphingosine 
was converted to the two C3-epimeric 1,4-diprotected 
azido-phytosphingosine derivatives 6-7.15
Given the electron withdrawing azido group 
presumably promoted the undesired elimination reaction, 
it was decided to first convert the azido group to the 
required long-chain amido moiety. Hence, Staudinger 
reduction, followed by acylation with hexacosanoic acid 
and EDC gave the ceramides 9 and 10, which were now 
successfully converted to the phthalimides via a 
Mitsunobu protocol to afford the desired 3-phthalimido-
phytosphingosine acceptors 11 and 12 after deprotection 
of the trityl group with zinc(II)-dibromide.  
 Unfortunately, 
all attempts to effect invertive phthalimide introduction 
via a Mitsunobu reaction resulted in an elimination side-
reaction to give 8, regardless of the configuration at C-3 
or the O-1 protecting group (see Supporting information). 
The E-configuration of the double bond in 8 was 




phytosphingosine 11 and 3-phthalimido-D-xylo-
phytosphingosine 12 with galactosyl fluoride 13 afforded 
the desired 3-amino-α-GalCer analogues 2 and 3, after 
final deprotection operations.  
 
                                                     
13 Llaveria, J.; Diaz, Y.; Matheu, M.I.; Castillon, S. Org. Lett. 2008, 
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(i) PMe3, THF, rt, 2 h
(ii) NaOH 1 M, rt, 2 h
(iii) C25H51COOH, EDC, CH2Cl2, rt, 18 h
13
(i) phthalimide, DIAD, PPh3, THF, 
toluene, rt, 18h
SnCl2, AgClO4, THF, 














(ii) ZnBr2, CH2Cl2/iPrOH: 85/15,
rt, 8 h
(i) H2, Pd black, CHCl3/EtOH: 1/1, 3 h




Scheme 2. Synthesis of the D-ribo and L-lyxo glycosidation 

































phthalimide, DIAD, PPh3, 
THF, toluene, rt, 18 h
(i) HF.pyridine, THF/pyridine,
0 °C, 0.5 h
(ii) TrCl, DMAP, pyridine, 
70 °C, 22 h
(ii) ZnBr2, CH2Cl2/iPrOH: 
85/15, rt, overnight
(i) BnBr, NaH, DMF,
0 °C-rt, 14 h
 
 
Towards the synthesis of the 4-amino-4-deoxy-α-
GalCer analogues 4 and 5, the 4-phtalimido-substituted 
phytosphingosine precursors with the natural D-ribo- (22) 
and L-lyxo-configuration (23) were first prepared in 5 
steps from the advanced intermediates 16 and 17 (Scheme 
2), again accessible from D-ribo-phytosphingosine.  
TMSOTf-promoted galactosidation of the 4-deoxy-4-
phthalimido-D-ribo-phytosphingosine 22 with the 
trichloroacetimidate donor 2417 afforded the α-glycoside 
without notable formation of the β-glycoside (Scheme 3). 
Interestingly, Staudinger reduction of the glycoside 25 led 
to the intramolecular formation of the amidine 27, 
presumably via the aza-Wittig mechanism.18 To 
circumvent this side-reaction, it was decided to perform a 
protecting group switch to give the corresponding 
dibenzylamino group (28), which allowed uncomplicated 
Staudinger reduction to give the 2-NH2
Similarly, glycosidation of the 4-deoxy-4-phthalimido-
L-lyxo-phytosphingosine 23 afforded the α-glycoside 26 
in 81% yield. In this case Staudinger reduction led to the 
desired free amine and a relatively small amount of the 
amidine, which could be efficiently removed after 
acylation of the former. Debenzylation, followed by final 
deprotection of the phthalimide with methylamine, gave 
the desired 4-amino-4-deoxy-α-galactosyl-L-lyxo-
phytoceramide 5.  
 group. 
Subsequent acylation with hexacosanoic acid and final 
deprotection afforded the desired 4-amino-4-deoxy-α-
galactosyl-D-ribo-phyto-ceramide 4.  
 
                                                     
17 (a) Plettenburg, O.; Bodmer-Narkevitch, V.; Wong, C.H. J. Org. 
Chem. 2002, 67, 4559; (b) Koeman, F.A.W.; Kamerling, J.P.; 
Vliegenthart, J.F.G. Tetrahedron 1993, 49, 5291; (c) Figueroa-Peréz, S.; 
Schmidt, R.R. Carbohydrate Res. 2000, 328, 95. 
18 Molina, P.; Vilaplasa, M.J. Synthesis 1994, 1197. 
 
Scheme 3. Synthesis of the 4-amino-4-deoxy-α-GalCer 































-20 °C, 1 h
(i) PMe3, THF, rt, 2 h
(i) MeNH2 in EtOH (8 M), reflux, 84 h
(ii) BnBr, K2CO3, MeCN, 40 °C, 6 d
(i) PMe3, THF, rt, 2 h 



















(i) PMe3, THF, rt, 2 h




(ii) NaOH 1 M, rt, 2 h
(iii) C25H51COOH, EDC, 
CH2Cl2, rt, 18 h
(iv) H2, Pd black, 
CHCl3/EtOH: 1/1, 4 h
(iii) C25H51COOH, EDC, 
CH2Cl2, rt, 18 h
(i) H2, Pd black, CHCl3/EtOH: 1/3, 4 h
(ii) MeNH2 in EtOH (8 M), reflux, 2 d
 
 
To compare the cytokine profile induced by the amino-
modified analogues with α-GalCer, serum cytokine levels 
were measured after IP injection of glycolipids 1-5 into 
C57Bl/6 mice (Figure 2). Following injection of the 3-
amino epimers 2 and 3, low levels of IL-4 were detected, 
and als IFN-γ levels were drastically lower compared to 
α-GalCer. On the other hand, a trend towards a more 
moderate reduction of IFN-γ was observed after 
stimulation with the 4-amino epimers 4 and 5. 
Surface plasmon resonance was used to measure the 
binding kinetics of a soluble mouse Vα14i TCR for the 
complex of mCD1d plus 1, 2 and 4. Compared to α-
GalCer (KD = 12.8 nM), the TCR showed a 13-fold 
reduced binding affinity to CD1d loaded with the 3-amino 
analogue 2 (KD = 163 nM) and a 125-fold drop in affinity 
for the 4-CD1d complex (KD = 1.7 µM). While the 
association of the TCR is 2x slower for analog 4 
(ka=2.21x104 1/Ms) and 6.5x slower for 2 (ka=6.1x104 
1/Ms) the TCR dissociates 25x faster from the amino 
analog 4 (kd
In summary, we showed that, despite its reasonable 
affinity for the TCR when complexed with CD1d, 
analogue 2 shows a very small cytokine response, while 
an opposite trend is observed for analogue 4. These 
findings conflict with current hypotheses, which, however 
have been inferred mainly from studies involving 
analogues with altered aliphatic chains. While such 
alterations are hidden from the TCR contact surface, this 
is different for the amino modifications in this study. 
Indeed, as highlighted by the crystal structure of the 
ternary mCD1d-α-GalCer-TCR,
= 0.037x1/s) and 7.5x faster for 2 (0.01x1/s). 
Therefore, the 3’- and 4’-amino modification significantly 
affect the overall stability of the TCR  interaction. 
 the 3-OH group is not 
only interacting with CD1d, but also exposed to the TCR 
to form a hydrogen bond with Arg-95 (of the CDR3α 
unit). Possibly, when protonated, the 3-amino group of 2 
interacts unfavorably with Arg-95, thereby leading to 
suboptimal activation of the TCR. 
 
 
Figure 2. INF-γ and IL-4 secretion after intraperitoneal 
injection of α-GalCer (1) and 2-5 in mice (* P < 0.01 vs α-
GalCer). 
 
In conclusion, the present amine-modified analogues 
indicate that, although TCR affinity probably accounts to 
some degree for the quality of responses mediated by 
iNKT cells, subtle changes to α-GalCer may afford 
analogues with diminished capacity to provoke activation 
of the iNKT cells, despite good affinity for the TCR.   
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